Skin, Skin infections, inflammations
Top Treatment Plans for Resistant Skin Infections Today
Mar
Resistant skin infections pose a significant challenge in modern healthcare, leading to prolonged treatments, increased healthcare costs, and poorer patient outcomes. As antibiotic resistance continues to rise, it is crucial for healthcare providers to stay updated on the latest treatment strategies to effectively manage these stubborn infections.
This article explores the current landscape of resistant skin infections, diagnostic approaches, and cutting-edge treatment options, including antibiotic therapy, antimicrobial peptides, phage therapy, and photodynamic therapy. Additionally, we will discuss preventive strategies and future research directions to combat the growing threat of resistant skin infections.
Current Landscape of Resistant Skin Infections
Prevalence and impact of resistant skin infections
Resistant skin infections have become increasingly prevalent in recent years, affecting millions of people worldwide. These infections, caused by pathogens that have developed resistance to commonly used antibiotics, can lead to prolonged illness, increased healthcare costs, and even life-threatening complications[1]. The impact of resistant skin infections extends beyond individual patients, placing a significant burden on healthcare systems and society as a whole.
Common pathogens and their resistance mechanisms
Several pathogens are notorious for causing resistant skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug-resistant Pseudomonas aeruginosa. These pathogens employ various resistance mechanisms, such as altered target sites, efflux pumps, and production of enzymes that inactivate antibiotics[2]. Understanding these resistance mechanisms is crucial for developing effective treatment strategies.
| Pathogen | Resistance Mechanisms | Associated Infections |
|---|---|---|
| MRSA | Altered penicillin-binding proteins | Skin and soft tissue infections, surgical site infections |
| VRE | Modified cell wall precursors | Wound infections, diabetic foot ulcers |
| Multidrug-resistant P. aeruginosa | Efflux pumps, production of β-lactamases | Burn infections, chronic wounds |
Challenges in treating resistant skin infections
Treating resistant skin infections presents several challenges for healthcare providers. The limited availability of effective antibiotics, the potential for further resistance development, and the presence of biofilms that protect pathogens from antimicrobial agents all contribute to the difficulty in managing these infections[3]. Additionally, patients with compromised immune systems or underlying chronic conditions may be more susceptible to resistant skin infections and face greater challenges in treatment.
Importance of developing effective treatment plans
Given the significant impact of resistant skin infections on patient health and healthcare systems, it is crucial to develop effective treatment plans that account for the unique challenges posed by these infections. A comprehensive approach that combines accurate diagnosis, targeted antibiotic therapy, and preventive measures is essential to improve patient outcomes and limit the spread of resistance.
Diagnostic Approaches for Resistant Skin Infections
Clinical presentation and physical examination
Diagnosing resistant skin infections begins with a thorough clinical assessment. Healthcare providers should be vigilant for signs and symptoms suggestive of infection, such as erythema, warmth, swelling, and purulent discharge. The presence of necrotic tissue, delayed healing, or atypical presentations may indicate a resistant infection[4]. A comprehensive physical examination, including an assessment of the patient’s overall health status and any underlying conditions, is essential for guiding diagnostic and treatment decisions.
Microbiological testing and susceptibility profiles
Microbiological testing plays a crucial role in identifying the causative pathogen and determining its susceptibility to antibiotics. Wound cultures, obtained through swabs or tissue biopsies, should be performed to isolate the pathogen[5]. Antimicrobial susceptibility testing, such as disk diffusion or broth microdilution, helps determine the most effective antibiotics for treatment. Interpreting susceptibility profiles requires expertise and consideration of local resistance patterns.
Molecular diagnostic techniques
Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and whole-genome sequencing (WGS), are increasingly used to rapidly identify pathogens and detect resistance genes. These methods can provide results within hours, allowing for earlier initiation of targeted therapy[6]. However, the availability and cost of molecular diagnostics may limit their widespread use in some settings.
| Method | Advantages | Limitations |
|---|---|---|
| Wound cultures | Widely available, identifies causative pathogen | Slow turnaround time, may not detect all resistant strains |
| Molecular diagnostics (PCR, WGS) | Rapid results, detects specific resistance genes | Higher cost, may not be widely available |
Imaging modalities for assessing infection severity
Imaging modalities, such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), can provide valuable information about the extent and severity of resistant skin infections. These techniques can help identify underlying bone involvement (osteomyelitis), abscesses, or necrotizing fasciitis, guiding surgical intervention and management decisions.
- Ultrasound: Useful for detecting superficial abscesses and evaluating soft tissue involvement
- CT: Helps assess deeper soft tissue structures and bone involvement
- MRI: Provides detailed imaging of soft tissues and can detect early osteomyelitis
Antibiotic Therapy for Resistant Skin Infections
Empiric and targeted antibiotic selection
Selecting appropriate antibiotics for resistant skin infections involves a balance between empiric therapy and targeted treatment based on susceptibility results. Empiric therapy should cover the most likely pathogens, including MRSA and other resistant organisms, based on local epidemiology and patient risk factors[7]. Once susceptibility profiles are available, antibiotic therapy should be tailored to the specific pathogen and resistance pattern to optimize outcomes and minimize the risk of further resistance development.
Dosing and duration of antibiotic therapy
Appropriate dosing and duration of antibiotic therapy are critical for effectively treating resistant skin infections while minimizing the risk of adverse effects and resistance development. Higher doses and longer durations may be necessary for severe infections or those involving deeper tissue structures[8]. However, prolonged antibiotic exposure can increase the risk of resistance and should be avoided when possible. Monitoring clinical response and adjusting therapy based on patient progress is essential.
| Antibiotic Class | Examples | Activity Against Resistant Pathogens |
|---|---|---|
| Glycopeptides | Vancomycin, Teicoplanin | MRSA, VRE |
| Oxazolidinones | Linezolid, Tedizolid | MRSA, VRE |
| Lipopeptides | Daptomycin | MRSA, VRE |
| Fifth-generation cephalosporins | Ceftaroline, Ceftobiprole | MRSA |
Combination therapy and synergistic effects
Combination antibiotic therapy may be considered for severe or recalcitrant resistant skin infections. Using antibiotics with different mechanisms of action can provide synergistic effects and improve treatment outcomes[9]. For example, combining a glycopeptide with an aminoglycoside or rifampin has shown promise in treating MRSA infections. However, the potential for increased adverse effects and drug interactions should be carefully considered when using combination therapy.
Monitoring for adverse effects and drug interactions
Close monitoring for adverse effects and drug interactions is crucial when using antibiotics for resistant skin infections. Nephrotoxicity, hepatotoxicity, and hematologic abnormalities are among the potential side effects of many anti-MRSA agents. Additionally, drug interactions can occur between antibiotics and other medications, necessitating dose adjustments or alternative therapy. Regular laboratory monitoring and clinical assessment can help detect and manage adverse effects promptly.
Antimicrobial Peptides and Their Potential in Treating Resistant Skin Infections
Overview of antimicrobial peptides (AMPs)
Antimicrobial peptides (AMPs) are a diverse group of small, cationic peptides produced by various organisms as part of their innate immune response. These peptides exhibit broad-spectrum antimicrobial activity against bacteria, fungi, and viruses, making them promising candidates for treating resistant skin infections[10]. AMPs can be isolated from natural sources or synthetically designed, offering the potential for optimization and targeted delivery.
Mechanisms of action against resistant pathogens
AMPs exert their antimicrobial effects through multiple mechanisms, which reduces the likelihood of resistance development. The primary mode of action involves disrupting bacterial cell membranes, leading to cell lysis and death. Additionally, AMPs can inhibit essential cellular processes, such as DNA replication, protein synthesis, and cell wall formation[11]. The rapid and multi-faceted action of AMPs makes them particularly effective against resistant pathogens, as multiple simultaneous mutations would be required for resistance to develop.
Advantages of AMPs over conventional antibiotics
AMPs offer several advantages over conventional antibiotics in treating resistant skin infections. Their broad-spectrum activity allows for effective treatment of infections caused by a wide range of pathogens, including those with resistance to multiple antibiotics. AMPs also have a lower propensity for inducing resistance, as their mechanisms of action are less specific than those of traditional antibiotics[12]. Additionally, AMPs can modulate the immune response, promoting wound healing and reducing inflammation, which is particularly beneficial in the context of skin infections.
Challenges and limitations of AMP therapy
Despite their promising potential, several challenges and limitations must be addressed before AMPs can be widely used in clinical practice. These include:
- Stability: AMPs may be susceptible to degradation by proteases in the body, reducing their effectiveness.
- Toxicity: Some AMPs can exhibit toxicity towards mammalian cells, requiring careful design and modification to minimize side effects.
- Manufacturing: Large-scale production of AMPs can be challenging and costly, limiting their availability.
- Delivery: Ensuring targeted delivery of AMPs to the site of infection while minimizing systemic exposure is crucial for optimal efficacy and safety.
Current research and future directions
Ongoing research aims to address the challenges associated with AMP therapy and optimize their potential for treating resistant skin infections. Strategies include modifying AMP structures to improve stability and reduce toxicity, developing novel delivery systems for targeted application, and exploring synergistic combinations of AMPs with conventional antibiotics. As our understanding of AMPs expands, their role in combating resistant skin infections is expected to grow, offering a promising alternative to traditional antibiotic therapy.
Phage Therapy for Resistant Skin Infections
Principles of phage therapy
Phage therapy involves the use of bacteriophages, which are viruses that specifically infect and lyse bacterial cells, to treat bacterial infections. This targeted approach offers a promising alternative to antibiotics, particularly in the context of resistant skin infections[13]. Phages can be isolated from natural sources, such as soil or water, and then purified and amplified for therapeutic use. The specificity of phages towards their bacterial hosts minimizes the risk of collateral damage to beneficial microbes and reduces the likelihood of resistance development.
Advantages of phage therapy over antibiotics
Phage therapy offers several advantages over traditional antibiotics in treating resistant skin infections. Phages are highly specific to their bacterial targets, minimizing the risk of disrupting the normal skin microbiome and reducing the potential for side effects. Additionally, phages can evolve alongside their bacterial hosts, adapting to counter resistance mechanisms[14]. This dynamic relationship between phages and bacteria makes phage therapy a promising approach for combating the growing threat of antibiotic resistance.
Challenges and limitations of phage therapy
Despite the potential benefits of phage therapy, several challenges and limitations must be addressed for its successful implementation in treating resistant skin infections. These include:
- Specificity: The high specificity of phages can be a double-edged sword, as it may require the use of multiple phages or phage cocktails to target different strains or species of bacteria.
- Immunogenicity: Phages can trigger an immune response in the body, potentially reducing their effectiveness or causing adverse reactions.
- Pharmacokinetics: Ensuring that phages reach the site of infection at sufficient concentrations and remain active long enough to exert their therapeutic effects can be challenging.
- Regulatory hurdles: The development and approval of phage therapy face unique regulatory challenges, as phages do not fit neatly into existing drug categories[15].
Current research and future directions
Ongoing research aims to address the challenges associated with phage therapy and optimize its potential for treating resistant skin infections. Strategies include engineering phages to enhance their specificity, stability, and penetration into biofilms, as well as developing phage cocktails to broaden the spectrum of activity. Combination therapy involving phages and antibiotics is also being explored to maximize therapeutic efficacy and minimize the risk of resistance development. As the field of phage therapy advances, its role in managing resistant skin infections is expected to expand, offering a much-needed alternative to traditional antibiotic therapy.
Photodynamic Therapy for Resistant Skin Infections
Principles of photodynamic therapy (PDT)
Photodynamic therapy (PDT) is a promising alternative approach for treating resistant skin infections. PDT involves the use of a photosensitizing agent, which is activated by light of a specific wavelength, generating reactive oxygen species that can kill bacterial cells[16]. The localized nature of PDT minimizes systemic side effects and reduces the risk of resistance development, as the mechanism of action differs from that of traditional antibiotics. PDT can be used as a standalone treatment or in combination with other therapeutic modalities to enhance their effectiveness.
Advantages of PDT over conventional antibiotics
PDT offers several advantages over conventional antibiotics in treating resistant skin infections. The non-specific mechanism of action of PDT, which targets multiple bacterial structures and pathways, makes it less susceptible to resistance development compared to antibiotics with a single target. Additionally, PDT can be effective against a broad spectrum of pathogens, including those with resistance to multiple antibiotics[17]. The localized nature of PDT also minimizes the risk of systemic side effects and reduces the impact on the normal skin microbiome.
Photosensitizers and light sources used in PDT
Various photosensitizers have been investigated for use in PDT for resistant skin infections. These include porphyrins, chlorins, and phenothiazines, among others. The choice of photosensitizer depends on factors such as the target pathogen, the depth of the infection, and the desired wavelength of light activation. Light sources used in PDT can range from light-emitting diodes (LEDs) to lasers, with wavelengths tailored to the specific photosensitizer employed[18].
Challenges and limitations of PDT
While PDT holds promise for treating resistant skin infections, several challenges and limitations must be addressed. These include:
- Penetration depth: The effectiveness of PDT may be limited in deep-seated infections or those involving thick, hyperkeratotic skin.
- Photosensitivity: Some photosensitizers can cause prolonged skin photosensitivity, requiring patients to avoid sunlight exposure for a period after treatment.
- Pain and discomfort: The activation of photosensitizers can cause pain and discomfort during treatment, which may require the use of anesthetics or analgesics.
- Cost and accessibility: The specialized equipment and expertise required for PDT may limit its accessibility and increase treatment costs compared to conventional antibiotics.
Current research and future directions
Ongoing research aims to optimize PDT for treating resistant skin infections by developing novel photosensitizers with improved specificity, penetration, and safety profiles. Strategies to enhance the delivery of photosensitizers, such as nanoparticle formulations and topical delivery systems, are also being explored. Combination therapy involving PDT and other antimicrobial agents, such as antibiotics or antimicrobial peptides, is another area of active investigation. As the evidence base for PDT in treating resistant skin infections grows, its role in clinical practice is expected to expand, offering a valuable tool in the fight against antibiotic resistance.
Preventive Strategies for Reducing Resistant Skin Infections
Importance of prevention in combating antibiotic resistance
Preventing the spread of resistant skin infections is crucial in the fight against antibiotic resistance. By reducing the incidence of these infections, the need for antibiotic treatment decreases, slowing the emergence and spread of resistant pathogens[19]. Preventive strategies should focus on minimizing the risk factors associated with resistant skin infections, such as inadequate hygiene, skin barrier dysfunction, and exposure to contaminated environments. A comprehensive approach involving healthcare providers, patients, and the community is necessary to effectively prevent the spread of resistant skin infections.
Infection control measures in healthcare settings
Healthcare settings, such as hospitals and long-term care facilities, are high-risk environments for the transmission of resistant skin infections. Implementing strict infection control measures is essential to prevent the spread of these infections among patients and healthcare workers. Key strategies include:
- Hand hygiene: Promoting proper handwashing techniques and the use of alcohol-based hand sanitizers among healthcare workers and patients.
- Personal protective equipment (PPE): Ensuring the appropriate use of gloves, gowns, and masks to minimize the risk of transmission.
- Environmental cleaning and disinfection: Regularly cleaning and disinfecting high-touch surfaces and patient care equipment to reduce the presence of pathogens[20].
- Isolation precautions: Implementing contact precautions for patients with known or suspected resistant skin infections to prevent transmission to others.
Antimicrobial stewardship programs
Antimicrobial stewardship programs aim to optimize antibiotic use and minimize the development of resistance. These programs involve a multidisciplinary approach, including physicians, pharmacists, and infection control specialists, to ensure that antibiotics are used appropriately and only when necessary. Strategies employed in antimicrobial stewardship programs include:
- Prescribing guidelines: Developing and implementing evidence-based guidelines for the appropriate use of antibiotics in the treatment of skin infections.
- Antibiotic de-escalation: Streamlining antibiotic therapy based on culture results and clinical response to minimize the duration of broad-spectrum antibiotic exposure.
- Education and feedback: Providing ongoing education to healthcare providers on the appropriate use of antibiotics and offering feedback on prescribing patterns[21].
Patient and community education
Educating patients and the community about the prevention of resistant skin infections is essential for reducing their spread. Key messages should include:
- Proper wound care: Encouraging patients to keep wounds clean and covered, and to seek medical attention for signs of infection.
- Personal hygiene: Promoting regular handwashing, bathing, and the use of clean clothing and bedding to minimize the risk of infection.
- Antibiotic awareness: Educating patients about the appropriate use of antibiotics and the risks associated with their misuse, such as the development of resistance.
By implementing these preventive strategies at the healthcare, community, and individual levels, the incidence of resistant skin infections can be reduced, slowing the spread of antibiotic resistance and preserving the effectiveness of available treatment options.
Future Directions and Research Priorities
Development of novel antimicrobial agents
The ongoing threat of antibiotic resistance in skin infections necessitates the development of novel antimicrobial agents with unique mechanisms of action. Research efforts should focus on identifying and characterizing new antimicrobial compounds, such as antimicrobial peptides, bacteriocins, and small molecules, that can effectively target resistant pathogens[22]. Additionally, exploring the potential of combination therapy, involving multiple antimicrobial agents with synergistic effects, could help to overcome resistance and improve treatment outcomes.
Advancing diagnostic technologies
Rapid and accurate diagnosis of resistant skin infections is crucial for guiding appropriate treatment and preventing the spread of resistance. Future research should prioritize the development of advanced diagnostic technologies, such as point-of-care testing, molecular diagnostics, and next-generation sequencing, to enable the swift identification of resistant pathogens and their resistance profiles[23]. Improved diagnostic capabilities will facilitate targeted therapy, reducing the unnecessary use of broad-spectrum antibiotics and minimizing the selection pressure for resistance.
Investigating the role of the skin microbiome
The skin microbiome plays a critical role in maintaining skin health and preventing infections. Understanding the complex interactions between the skin microbiome, pathogens, and the host immune system could provide valuable insights into the development and management of resistant skin infections. Future research should explore the potential of microbiome-based therapies, such as probiotics and prebiotics, to restore the balance of the skin microbiome and enhance its protective functions against resistant pathogens.
Enhancing infection prevention and control measures
Effective infection prevention and control measures are essential for limiting the spread of resistant skin infections in healthcare settings and the community. Future research should focus on developing and evaluating innovative strategies to improve hand hygiene compliance, optimize environmental cleaning and disinfection protocols, and promote the appropriate use of personal protective equipment. Additionally, investigating the role of behavioral and organizational factors in the implementation and sustainability of infection control measures could help to identify barriers and facilitators to their success[24].
Promoting antibiotic stewardship and public awareness
Antibiotic stewardship programs have proven effective in reducing the inappropriate use of antibiotics and slowing the emergence of resistance. Continued research is needed to refine and expand these programs, particularly in outpatient and community settings where antibiotic misuse is common. Furthermore, promoting public awareness about the dangers of antibiotic resistance and the importance of judicious antibiotic use through educational campaigns and community engagement initiatives is crucial for driving behavior change and reducing the demand for unnecessary antibiotics.
By prioritizing these research areas and translating the findings into clinical practice and public health interventions, we can make significant strides in combating the growing threat of resistant skin infections and preserving the effectiveness of our antimicrobial arsenal for future generations.
Frequently Asked Questions
Resistant skin infections are caused by bacteria that have developed resistance to commonly used antibiotics, making them difficult to treat. These infections can affect various layers of the skin and may spread to other parts of the body if left untreated.
The most common types of resistant skin infections include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug-resistant Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Risk factors for developing resistant skin infections include prolonged hospitalization, previous antibiotic use, weakened immune system, chronic wounds, and close contact with individuals who have resistant skin infections.
To prevent the spread of resistant skin infections, practice good hygiene, such as washing your hands regularly with soap and water, keeping cuts and wounds clean and covered, avoiding sharing personal items like towels or razors, and following proper infection control measures in healthcare settings.
Treatment options for resistant skin infections may include targeted antibiotics based on the specific pathogen and its resistance profile, combination therapy with multiple antibiotics, topical treatments such as antimicrobial dressings or ointments, and alternative therapies like photodynamic therapy or bacteriophage therapy.
Healthcare providers can help combat antibiotic resistance in skin infections by implementing antimicrobial stewardship programs, which promote the judicious use of antibiotics, prescribing antibiotics only when necessary, and selecting the most appropriate antibiotic based on the pathogen and its resistance profile. They should also educate patients about the importance of completing the prescribed course of antibiotics and not sharing them with others.
Research plays a crucial role in addressing the challenge of resistant skin infections by focusing on the development of novel antimicrobial agents, advancing diagnostic technologies for rapid identification of resistant pathogens, investigating the role of the skin microbiome in preventing infections, and enhancing infection prevention and control measures.
Reference list
- Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629-641.
- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277-283.
- Guillamet CV, Kollef MH. How to stratify patients at risk for resistant bugs in skin and soft tissue infections? Curr Opin Infect Dis. 2016;29(2):116-123.
- Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):109-115.
- Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65 Suppl 3:iii35-44.
- David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616-687.
- Gould IM, David MZ, Esposito S, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39(2):96-104.
- Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med. 2012;79(1):57-66.
- Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22 Suppl 2:S27-36.
- Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR gram-negative bacteria. Front Med (Lausanne). 2019;6:74.
- Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44(6):e397-412.
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.
- Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc. 2014;89(10):1436-1451.
- Chastain DB, Keri LH. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1027-1033.
- Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179.
- Dryden M, Cooke J, Salib R, et al. Reactive oxygen: a novel antimicrobial mechanism for targeting biofilm-associated infection. J Glob Antimicrob Resist. 2017;8:186-191.
- Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017;16(7):457-471.
- Hua L, Cohen TS, Shi Y, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015;59(8):4526-4532.
- Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016;5:15.
- Zaidi S, Misba L, Khan AU. Nano-therapeutics: A revolution in infection control in post antibiotic era. Nanomedicine. 2017;13(7):2281-2301.
- Prax M, Bertram R. Metabolic aspects of bacterial persisters. Front Cell Infect Microbiol. 2014;4:148.
- Hay SI, Rao PC, Dolecek C, et al. Measuring and mapping the global burden of antimicrobial resistance. BMC Med. 2018;16(1):78.
- van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin North Am. 2016;30(2):377-390.
- Tacconelli E, Sifakis F, Harbarth S, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;18(3):e99-e106.
